Skip to main content

Peer Review reports

From: Approaches to discontinuing efalizumab: an open-label study of therapies for managing inflammatory recurrence

Original Submission
11 May 2006 Submitted Original manuscript
23 Jun 2006 Reviewed Reviewer Report - Dan Pearce
7 Jul 2006 Reviewed Reviewer Report - Jennifer Cather
15 Aug 2006 Author responded Author comments - Kim Papp
Resubmission - Version 2
15 Aug 2006 Submitted Manuscript version 2
25 Aug 2006 Author responded Author comments - Kim Papp
Resubmission - Version 3
25 Aug 2006 Submitted Manuscript version 3
13 Sep 2006 Reviewed Reviewer Report - Jennifer Cather
2 Oct 2006 Reviewed Reviewer Report - Dan Pearce
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
26 Oct 2006 Editorially accepted
26 Oct 2006 Article published 10.1186/1471-5945-6-9

You can find further information about peer review here.

Back to article page